Share Price and Basic Stock Data
Last Updated: October 16, 2025, 8:58 pm
| PEG Ratio | -6.33 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Gufic BioSciences Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹3,658 Cr. The company reported sales of ₹691 Cr for the fiscal year ending March 2023, which rose to ₹807 Cr in March 2024 and further to ₹820 Cr in March 2025. The quarterly sales figures indicate a robust upward trend, with ₹215 Cr recorded in September 2023, an increase from ₹195 Cr in June 2023. This growth trajectory reflects Gufic’s solid positioning in the pharmaceutical market, driven by increasing demand for its products. However, the company faced a decline in sales compared to the previous year, as evidenced by the drop from ₹779 Cr in March 2022 to ₹691 Cr in March 2023, highlighting potential volatility in revenue streams. The operating profit margin (OPM) stood at 20% for FY 2023, indicating efficient management of operational costs relative to sales. Overall, Gufic’s revenue trends demonstrate resilience but also underline the need for strategic initiatives to enhance growth stability.
Profitability and Efficiency Metrics
Profitability metrics for Gufic BioSciences reveal mixed results. The net profit for the fiscal year 2023 was ₹80 Cr, which declined to ₹70 Cr in FY 2025, indicating challenges in maintaining profitability levels. The earnings per share (EPS) also reflected this trend, declining from ₹8.22 in FY 2023 to ₹6.97 in FY 2025. The company’s return on equity (ROE) stood at 12.3%, while the return on capital employed (ROCE) was reported at 13.2%. These figures suggest that Gufic is generating a decent return on its equity but faces challenges in capital efficiency. The interest coverage ratio was robust at 9.64x, indicating that Gufic can comfortably meet its interest obligations. However, the cash conversion cycle lengthened to 197 days in FY 2025, which signals inefficiencies in managing working capital. Overall, while Gufic maintains a good interest coverage, the profitability metrics indicate the need for enhanced operational efficiency.
Balance Sheet Strength and Financial Ratios
Gufic BioSciences’ balance sheet reflects a total borrowing of ₹336 Cr against reserves of ₹591 Cr, which provides a debt-to-equity ratio of 0.59, indicating a moderate level of financial leverage. This level of debt is manageable, especially considering the interest coverage ratio of 9.64x, which suggests that the company can comfortably service its debt obligations. The current ratio stood at 1.61, indicating that Gufic has sufficient short-term assets to cover its liabilities, which is favorable for liquidity. Additionally, the company’s book value per share was ₹53.11 as of March 2024, and the price-to-book value ratio is 5.33x, which is relatively high compared to industry norms, suggesting that the stock may be overvalued. The company also reported total assets of ₹1,170 Cr, reflecting robust asset growth. However, the increase in borrowings over the years warrants monitoring to ensure that it does not adversely impact financial stability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gufic BioSciences shows a strong promoter holding of 72.51%, which reflects significant confidence from the founders in the company’s prospects. Foreign Institutional Investors (FIIs) hold a minimal stake of 0.32%, while Domestic Institutional Investors (DIIs) have increased their stake to 3.38%, indicating a cautious but growing interest from institutional players. The public shareholding accounts for 23.81%, with a total of 31,876 shareholders as of March 2025. The gradual decline in promoter holding from 75% in late 2022 to the current level may raise questions about insider sentiment, but the stability in other investor categories suggests a balanced view of the company’s performance. The increase in DII holdings indicates a positive sentiment among domestic investors, which could reflect confidence in Gufic’s long-term growth strategy. Overall, while promoter stability remains strong, the low FII participation may indicate hesitance from foreign investors.
Outlook, Risks, and Final Insight
If margins sustain and Gufic successfully manages its operational efficiencies, the company could leverage its strong market position to enhance profitability. However, the risks associated with declining net profit and increasing borrowings need careful navigation. The lengthy cash conversion cycle presents a challenge that could hinder liquidity and operational flexibility. Additionally, external market conditions and competitive pressures could impact revenue growth. If Gufic can implement effective cost-control measures and enhance its product offerings, it may improve its profitability metrics and attract more institutional investment. The company’s ability to adapt to market changes while maintaining strong financial health will be crucial in determining its future performance. Overall, while Gufic BioSciences has a solid foundation, strategic focus on operational efficiency and market responsiveness will be essential for sustainable growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Gufic BioSciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 153 Cr. | 122 | 247/84.3 | 34.9 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,692 Cr. | 430 | 438/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.2 Cr. | 46.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.1 Cr. | 20.6 | 29.1/17.0 | 31.4 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,725.80 Cr | 1,182.47 | 49.99 | 193.63 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 165 | 175 | 177 | 173 | 195 | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 227 |
| Expenses | 132 | 142 | 143 | 141 | 160 | 176 | 165 | 161 | 167 | 166 | 174 | 178 | 195 |
| Operating Profit | 33 | 33 | 34 | 32 | 35 | 39 | 36 | 34 | 36 | 39 | 34 | 27 | 32 |
| OPM % | 20% | 19% | 19% | 19% | 18% | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 14% |
| Other Income | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 |
| Interest | 1 | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 |
| Depreciation | 4 | 5 | 6 | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 |
| Profit before tax | 28 | 27 | 27 | 24 | 28 | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 16 |
| Tax % | 26% | 26% | 25% | 24% | 26% | 25% | 25% | 26% | 26% | 26% | 26% | 26% | 26% |
| Net Profit | 21 | 20 | 20 | 18 | 21 | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 12 |
| EPS in Rs | 2.17 | 2.08 | 2.10 | 1.87 | 2.13 | 2.39 | 2.22 | 2.00 | 2.08 | 2.17 | 1.93 | 0.79 | 1.20 |
Last Updated: August 20, 2025, 10:00 am
Below is a detailed analysis of the quarterly data for Gufic BioSciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 227.00 Cr.. The value appears strong and on an upward trend. It has increased from 205.00 Cr. (Mar 2025) to 227.00 Cr., marking an increase of 22.00 Cr..
- For Expenses, as of Jun 2025, the value is 195.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 178.00 Cr. (Mar 2025) to 195.00 Cr., marking an increase of 17.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 5.00 Cr..
- For OPM %, as of Jun 2025, the value is 14.00%. The value appears strong and on an upward trend. It has increased from 13.00% (Mar 2025) to 14.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 9.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 5.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00%.
- For Net Profit, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 4.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.20. The value appears strong and on an upward trend. It has increased from 0.79 (Mar 2025) to 1.20, marking an increase of 0.41.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 148 | 201 | 245 | 306 | 351 | 379 | 488 | 779 | 691 | 807 | 820 | 844 |
| Expenses | 109 | 134 | 181 | 222 | 267 | 305 | 327 | 404 | 631 | 556 | 657 | 683 | 712 |
| Operating Profit | 12 | 14 | 20 | 23 | 39 | 46 | 52 | 84 | 148 | 135 | 150 | 136 | 132 |
| OPM % | 10% | 10% | 10% | 9% | 13% | 13% | 14% | 17% | 19% | 20% | 19% | 17% | 16% |
| Other Income | 1 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 3 | 3 | -0 | 4 | 3 |
| Interest | 4 | 4 | 6 | 6 | 9 | 10 | 14 | 14 | 5 | 8 | 17 | 25 | 28 |
| Depreciation | 2 | 4 | 4 | 4 | 4 | 5 | 14 | 16 | 19 | 22 | 17 | 21 | 24 |
| Profit before tax | 6 | 7 | 10 | 14 | 30 | 35 | 30 | 58 | 127 | 107 | 116 | 94 | 83 |
| Tax % | 32% | 36% | 29% | 37% | 45% | 38% | 25% | 23% | 24% | 25% | 26% | 26% | |
| Net Profit | 4 | 4 | 7 | 9 | 16 | 22 | 23 | 44 | 96 | 80 | 86 | 70 | 61 |
| EPS in Rs | 0.55 | 0.54 | 0.95 | 1.17 | 2.13 | 2.82 | 2.92 | 5.68 | 9.89 | 8.22 | 8.59 | 6.97 | 6.09 |
| Dividend Payout % | 9% | 9% | 5% | 4% | 2% | 2% | 2% | 2% | 1% | 1% | 1% | 1% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 75.00% | 28.57% | 77.78% | 37.50% | 4.55% | 91.30% | 118.18% | -16.67% | 7.50% | -18.60% |
| Change in YoY Net Profit Growth (%) | 0.00% | 75.00% | -46.43% | 49.21% | -40.28% | -32.95% | 86.76% | 26.88% | -134.85% | 24.17% | -26.10% |
Gufic BioSciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 17% |
| 3 Years: | 2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 25% |
| 3 Years: | -10% |
| TTM: | -29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 35% |
| 3 Years: | 16% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 22% |
| 3 Years: | 18% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 5:30 am
Balance Sheet
Last Updated: June 16, 2025, 12:03 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 18 | 19 | 26 | 30 | 46 | 68 | 120 | 164 | 259 | 338 | 523 | 591 |
| Borrowings | 33 | 33 | 43 | 57 | 80 | 98 | 126 | 62 | 64 | 334 | 333 | 336 |
| Other Liabilities | 52 | 67 | 75 | 84 | 104 | 106 | 152 | 157 | 188 | 179 | 227 | 232 |
| Total Liabilities | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 |
| Fixed Assets | 30 | 25 | 22 | 22 | 23 | 24 | 83 | 100 | 115 | 160 | 159 | 506 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 10 | 31 | 13 | 41 | 170 | 307 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Other Assets | 81 | 102 | 130 | 156 | 213 | 245 | 294 | 279 | 365 | 531 | 625 | 639 |
| Total Assets | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 |
Below is a detailed analysis of the balance sheet data for Gufic BioSciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
- For Reserves, as of Mar 2025, the value is 591.00 Cr.. The value appears strong and on an upward trend. It has increased from 523.00 Cr. (Mar 2024) to 591.00 Cr., marking an increase of 68.00 Cr..
- For Borrowings, as of Mar 2025, the value is 336.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 333.00 Cr. (Mar 2024) to 336.00 Cr., marking an increase of 3.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 232.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 227.00 Cr. (Mar 2024) to 232.00 Cr., marking an increase of 5.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,170.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,093.00 Cr. (Mar 2024) to 1,170.00 Cr., marking an increase of 77.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 506.00 Cr.. The value appears strong and on an upward trend. It has increased from 159.00 Cr. (Mar 2024) to 506.00 Cr., marking an increase of 347.00 Cr..
- For CWIP, as of Mar 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 307.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 285.00 Cr..
- For Investments, as of Mar 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 639.00 Cr.. The value appears strong and on an upward trend. It has increased from 625.00 Cr. (Mar 2024) to 639.00 Cr., marking an increase of 14.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,170.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,093.00 Cr. (Mar 2024) to 1,170.00 Cr., marking an increase of 77.00 Cr..
Notably, the Reserves (591.00 Cr.) exceed the Borrowings (336.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -21.00 | -19.00 | -23.00 | -34.00 | -41.00 | -52.00 | -74.00 | 22.00 | 84.00 | -199.00 | -183.00 | -200.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 85 | 82 | 102 | 78 | 97 | 107 | 103 | 93 | 71 | 109 | 149 | 140 |
| Inventory Days | 144 | 165 | 180 | 190 | 238 | 190 | 249 | 138 | 102 | 202 | 188 | 211 |
| Days Payable | 176 | 223 | 188 | 132 | 192 | 157 | 238 | 162 | 125 | 143 | 156 | 155 |
| Cash Conversion Cycle | 54 | 25 | 94 | 136 | 143 | 141 | 114 | 69 | 48 | 167 | 181 | 197 |
| Working Capital Days | 20 | 4 | 18 | 14 | 26 | 40 | 17 | 63 | 50 | 68 | 97 | 93 |
| ROCE % | 17% | 18% | 24% | 24% | 33% | 30% | 21% | 29% | 46% | 23% | 17% | 13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities Fund | 1,000,000 | 1.32 | 26.08 | 1,000,000 | 2025-04-22 17:25:34 | 0% |
| Quant Business Cycle Fund | 438,603 | 1.78 | 11.44 | 438,603 | 2025-04-22 17:25:34 | 0% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 23,073 | 0.13 | 0.6 | 23,073 | 2025-04-22 15:56:57 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 247 | 0.08 | 0.01 | 247 | 2025-04-22 17:25:34 | 0% |
| Groww Nifty Total Market Index Fund | 53 | 0 | 0 | 53 | 2025-04-22 17:25:34 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 1.00 | 1.00 |
| Basic EPS (Rs.) | 6.95 | 8.74 |
| Diluted EPS (Rs.) | 6.95 | 8.74 |
| Cash EPS (Rs.) | 9.05 | 10.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 59.94 | 53.11 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 59.94 | 53.11 |
| Revenue From Operations / Share (Rs.) | 81.75 | 80.44 |
| PBDIT / Share (Rs.) | 13.79 | 14.76 |
| PBIT / Share (Rs.) | 11.69 | 13.07 |
| PBT / Share (Rs.) | 9.39 | 11.54 |
| Net Profit / Share (Rs.) | 6.95 | 8.59 |
| NP After MI And SOA / Share (Rs.) | 6.95 | 8.59 |
| PBDIT Margin (%) | 16.87 | 18.35 |
| PBIT Margin (%) | 14.30 | 16.24 |
| PBT Margin (%) | 11.48 | 14.33 |
| Net Profit Margin (%) | 8.49 | 10.67 |
| NP After MI And SOA Margin (%) | 8.49 | 10.67 |
| Return on Networth / Equity (%) | 11.58 | 16.17 |
| Return on Capital Employeed (%) | 14.99 | 18.18 |
| Return On Assets (%) | 5.95 | 7.88 |
| Long Term Debt / Equity (X) | 0.21 | 0.28 |
| Total Debt / Equity (X) | 0.51 | 0.59 |
| Asset Turnover Ratio (%) | 0.72 | 0.00 |
| Current Ratio (X) | 1.61 | 1.61 |
| Quick Ratio (X) | 1.05 | 1.08 |
| Inventory Turnover Ratio (X) | 1.65 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 1.12 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.93 |
| Earning Retention Ratio (%) | 0.00 | 98.88 |
| Cash Earning Retention Ratio (%) | 0.00 | 99.07 |
| Interest Coverage Ratio (X) | 5.98 | 9.64 |
| Interest Coverage Ratio (Post Tax) (X) | 4.01 | 6.61 |
| Enterprise Value (Cr.) | 3655.21 | 3142.92 |
| EV / Net Operating Revenue (X) | 4.46 | 3.90 |
| EV / EBITDA (X) | 26.43 | 21.23 |
| MarketCap / Net Operating Revenue (X) | 4.12 | 3.52 |
| Retention Ratios (%) | 0.00 | 98.87 |
| Price / BV (X) | 5.61 | 5.33 |
| Price / Net Operating Revenue (X) | 4.12 | 3.52 |
| EarningsYield | 0.02 | 0.03 |
After reviewing the key financial ratios for Gufic BioSciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.74 (Mar 24) to 6.95, marking a decrease of 1.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.74 (Mar 24) to 6.95, marking a decrease of 1.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.05. This value is within the healthy range. It has decreased from 10.29 (Mar 24) to 9.05, marking a decrease of 1.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 59.94. It has increased from 53.11 (Mar 24) to 59.94, marking an increase of 6.83.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 59.94. It has increased from 53.11 (Mar 24) to 59.94, marking an increase of 6.83.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 81.75. It has increased from 80.44 (Mar 24) to 81.75, marking an increase of 1.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.79. This value is within the healthy range. It has decreased from 14.76 (Mar 24) to 13.79, marking a decrease of 0.97.
- For PBIT / Share (Rs.), as of Mar 25, the value is 11.69. This value is within the healthy range. It has decreased from 13.07 (Mar 24) to 11.69, marking a decrease of 1.38.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.39. This value is within the healthy range. It has decreased from 11.54 (Mar 24) to 9.39, marking a decrease of 2.15.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.59 (Mar 24) to 6.95, marking a decrease of 1.64.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.59 (Mar 24) to 6.95, marking a decrease of 1.64.
- For PBDIT Margin (%), as of Mar 25, the value is 16.87. This value is within the healthy range. It has decreased from 18.35 (Mar 24) to 16.87, marking a decrease of 1.48.
- For PBIT Margin (%), as of Mar 25, the value is 14.30. This value is within the healthy range. It has decreased from 16.24 (Mar 24) to 14.30, marking a decrease of 1.94.
- For PBT Margin (%), as of Mar 25, the value is 11.48. This value is within the healthy range. It has decreased from 14.33 (Mar 24) to 11.48, marking a decrease of 2.85.
- For Net Profit Margin (%), as of Mar 25, the value is 8.49. This value is within the healthy range. It has decreased from 10.67 (Mar 24) to 8.49, marking a decrease of 2.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.49. This value is within the healthy range. It has decreased from 10.67 (Mar 24) to 8.49, marking a decrease of 2.18.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.58. This value is below the healthy minimum of 15. It has decreased from 16.17 (Mar 24) to 11.58, marking a decrease of 4.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.99. This value is within the healthy range. It has decreased from 18.18 (Mar 24) to 14.99, marking a decrease of 3.19.
- For Return On Assets (%), as of Mar 25, the value is 5.95. This value is within the healthy range. It has decreased from 7.88 (Mar 24) to 5.95, marking a decrease of 1.93.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 0.28 (Mar 24) to 0.21, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.51. This value is within the healthy range. It has decreased from 0.59 (Mar 24) to 0.51, marking a decrease of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.72. It has increased from 0.00 (Mar 24) to 0.72, marking an increase of 0.72.
- For Current Ratio (X), as of Mar 25, the value is 1.61. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.61.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has decreased from 1.08 (Mar 24) to 1.05, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.65. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 1.65, marking an increase of 1.65.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.12 (Mar 24) to 0.00, marking a decrease of 1.12.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 0.93 (Mar 24) to 0.00, marking a decrease of 0.93.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.88 (Mar 24) to 0.00, marking a decrease of 98.88.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 99.07 (Mar 24) to 0.00, marking a decrease of 99.07.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has decreased from 9.64 (Mar 24) to 5.98, marking a decrease of 3.66.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.01. This value is within the healthy range. It has decreased from 6.61 (Mar 24) to 4.01, marking a decrease of 2.60.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,655.21. It has increased from 3,142.92 (Mar 24) to 3,655.21, marking an increase of 512.29.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 3. It has increased from 3.90 (Mar 24) to 4.46, marking an increase of 0.56.
- For EV / EBITDA (X), as of Mar 25, the value is 26.43. This value exceeds the healthy maximum of 15. It has increased from 21.23 (Mar 24) to 26.43, marking an increase of 5.20.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 24) to 4.12, marking an increase of 0.60.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 98.87 (Mar 24) to 0.00, marking a decrease of 98.87.
- For Price / BV (X), as of Mar 25, the value is 5.61. This value exceeds the healthy maximum of 3. It has increased from 5.33 (Mar 24) to 5.61, marking an increase of 0.28.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 24) to 4.12, marking an increase of 0.60.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gufic BioSciences Ltd:
- Net Profit Margin: 8.49%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.99% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.58% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.01
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 58.5 (Industry average Stock P/E: 49.99)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.51
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.49%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 37, First Floor, Kamala Bhavan II, Mumbai Maharashtra 400069 | corporaterelations@guficbio.com http://www.gufic.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jayesh P Choksi | Chairman & Managing Director |
| Mr. Pranav J Choksi | WholeTime Director & CEO |
| Mr. Pankaj J Gandhi | Whole Time Director |
| Mr. Dilip B Ghosh | Whole Time Director |
| Dr. Balram H Singh | Non Exe.Non Ind.Director |
| Mr. Shreyas K Patel | Independent Director |
| Mr. Shrirang V Vaidya | Independent Director |
| Dr. Anu S Auora | Independent Director |
| Dr. Rabi N Sahoo | Independent Director |
| Mr. Gopal M Daptari | Independent Director |
FAQ
What is the intrinsic value of Gufic BioSciences Ltd?
Gufic BioSciences Ltd's intrinsic value (as of 16 October 2025) is 345.49 which is 2.68% lower the current market price of 355.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,575 Cr. market cap, FY2025-2026 high/low of 504/285, reserves of ₹591 Cr, and liabilities of 1,170 Cr.
What is the Market Cap of Gufic BioSciences Ltd?
The Market Cap of Gufic BioSciences Ltd is 3,575 Cr..
What is the current Stock Price of Gufic BioSciences Ltd as on 16 October 2025?
The current stock price of Gufic BioSciences Ltd as on 16 October 2025 is 355.
What is the High / Low of Gufic BioSciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gufic BioSciences Ltd stocks is 504/285.
What is the Stock P/E of Gufic BioSciences Ltd?
The Stock P/E of Gufic BioSciences Ltd is 58.5.
What is the Book Value of Gufic BioSciences Ltd?
The Book Value of Gufic BioSciences Ltd is 60.0.
What is the Dividend Yield of Gufic BioSciences Ltd?
The Dividend Yield of Gufic BioSciences Ltd is 0.03 %.
What is the ROCE of Gufic BioSciences Ltd?
The ROCE of Gufic BioSciences Ltd is 13.2 %.
What is the ROE of Gufic BioSciences Ltd?
The ROE of Gufic BioSciences Ltd is 12.3 %.
What is the Face Value of Gufic BioSciences Ltd?
The Face Value of Gufic BioSciences Ltd is 1.00.